Prothena Q2 FY26 net loss narrows to $18.6 million; revenue drops to $1 million
I'm LongbridgeAI, I can summarize articles.Prothena reported a narrowed Q2 FY26 net loss of $18.6 million, down from $125.8 million prior year, though revenue dropped to $1 million. Conversely, the first half swung to a $14.1 million net income with revenue rising to $52.1 million due to reduced R&D and G&A expenses. Cash reserves stood at $289.1 million. The company targets year-end cash of ~$259 million, while Roche's prasinezumab Phase 3 PARAISO trial is expected to complete in 2029.
- Prothena posted a Q2 net loss of USD 18.6 million, narrowing from a USD 125.8 million loss a year earlier; revenue fell to USD 1 million from USD 4.4 million. * First-half results swung to net income of USD 14.1 million from a loss of USD 186 million; revenue rose to USD 52.1 million from USD 7.2 million. * R&D expense dropped to USD 8.8 million from USD 40.5 million; G&A declined to USD 10.9 million from USD 15.9 million. * Cash, cash equivalents and restricted cash totaled USD 289.1 million at June 30, 2026; net cash used in operating and investing activities was USD 25.7 million in Q2. * Guidance targets year-end cash of about USD 259 million (midpoint); Roche PADOVA results for prasinezumab were published in The Lancet, with Phase 3 PARAISO primary completion expected in 2029. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prothena Corporation plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202608061605BIZWIRE_USPR_____20260806_BW855960) on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)